In 2014, The FDA approved a Lp-PLA2 activity test by use of the PLAC® Test (diaDexus Inc, San Francisco, CA, USA) to predict cardiovascular disease in clinical practice. This evidence concerns the gene PLA2G7 and cardiovascular disorder.